BriaCell Therapeutics Corp. (TSE:BCT – Get Free Report)’s share price fell 20.9% during mid-day trading on Friday . The stock traded as low as C$4.27 and last traded at C$4.39. 93,500 shares changed hands during mid-day trading, an increase of 283% from the average session volume of 24,408 shares. The stock had previously closed at C$5.55.
BriaCell Therapeutics Trading Down 23.8%
The business has a 50-day moving average price of C$5.69 and a 200 day moving average price of C$8.73. The company has a market cap of C$30.67 million, a price-to-earnings ratio of -0.29 and a beta of 1.95.
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell’s lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers.
Recommended Stories
- Five stocks we like better than BriaCell Therapeutics
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
